-
156 Reads
|
0 Comments
|
December 1, 2015
.PROMETIC CONFIRMS PBI-4050’S EFFICACY IN PATIENTS SUFFERING FROM TYPE 2 DIABETES AND METABOLIC SYNDROME » Statistically and clinically significant decrease of glycated hemoglobin (HbA1c) at 12 weeks in an open label study » Significant improvement in physical parameters related to metabolic...
-
221 Reads
|
0 Comments
|
November 13, 2015
Today CC included two very valuable info: 5000$ worth of Pg by litre of plasma Starting in 2017! That's one year earlier than I anticipated! On that first year, there's a potential for 400 kl (Laval + Winnipeg) x 5000$/l = 2G$ but let's cut it in half to buffer us from delays and sales rampup. That's still 1G$! At 20% net margins it's worth ~ 35¢ of EPS. We...
-
124 Reads
|
0 Comments
|
November 4, 2015
ProMetic's plasminogen drug successfully used to treat plasminogen deficient infant in critical condition Severe clinical manifestations (including acute lung complications) significantly improved in a 20-month old infant Recommended plasminogen dose regimen provided efficacious clinical result LAVAL, QC, Nov. 4, 2015 /CNW...
-
315 Reads
|
0 Comments
|
November 3, 2015
Panmure Gordon Update It recognizes the purchase of Dyax by Shire for $5.9 B and says PLI's current valuation of only $1.2B is "harsh" in comparison and maintain its price at $4.26. See it or copy it at: http://docdro.id/KzwxjGl
-
403 Reads
|
0 Comments
|
October 1, 2015
comments from Canaccord: The news is more significant than people may think. ~ Investment Highlights • FDA provides validation for ‘4050 in IPF. We had viewed the pre-clinical data for PBI-4050 to be very supportive of its applicability in IPF. However, we believe that the FDA’s buy-in for a pivotal clinical program in IPF provides tremendous validation in...
-
254 Reads
|
0 Comments
|
September 29, 2015
Good morning Ric, We have already disclosed exactly what we expect to accomplish before year-end. If you go back to our Q2 results conference call and webcast presentation, you will see exactly what we said were the milestones we would be working on delivering before the year is over: Nothing has changed regarding that…………. Plasminogen: Further...
-
352 Reads
|
0 Comments
|
September 28, 2015
. Paradigm Resumes coverage: Buy; $3.75 Target Thanks, Franois, The report looks like the standard positive outlook. They mention the SP "pullback": "We believe the pullback in the share price is largely overdone and the market is undervaluing the numerous high-value drugs in advanced clinical trial phases. In our opinion, PLI’s low-volume high-value...
-
455 Reads
|
0 Comments
|
September 24, 2015
Media coverage on the GENERIUM Russian plasma purification facility construction Dear Readers, Please see below the link to a recent article published on the construction of the GENERIUM Russian plasma purification facility. http://www.outsourcing-pharma.com/Contract-Manufacturing/Swedish-engineering-firm-selected-to-design-76m-Russian-plasma-plant This project is referred to as the...